{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:19:15Z","timestamp":1791299955781,"version":"4.1.0"},"reference-count":109,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T00:00:00Z","timestamp":1391472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Dermatomyositis (DM), polymyositis (PM), necrotizing myopathy (NM) and inclusion body myositis (IBM) are four distinct subtypes of idiopathic inflammatory myopathies \u2013 in short myositis. Recent studies have shed some light on the unique pathogenesis of each entity. Some of the clinical features are distinct, but muscle biopsy is indispensable for making a reliable diagnosis. The use of magnetic resonance imaging of skeletal muscles and detection of myositis-specific autoantibodies have become useful additions to our diagnostic repertoire. Only few controlled trials are available to substantiate current treatment approaches for myositis and hopes are high that novel modalities will become available within the next few years. In this review we provide an up-to-date overview of the pathogenesis and diagnostic approach of myositis. We aim to present a guide towards therapeutic and general management.<\/jats:p>","DOI":"10.1111\/cei.12194","type":"journal-article","created":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T08:06:55Z","timestamp":1377590815000},"page":"349-358","source":"Crossref","is-referenced-by-count":113,"title":["Diagnosis, pathogenesis and treatment of myositis: recent advances"],"prefix":"10.1093","volume":"175","author":[{"given":"P -O","family":"Carstens","sequence":"first","affiliation":[{"name":"Clinic for Neurology, Institute for Multiple Sclerosis Research and Hertie Foundation, University Medical Centre G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Clinic for Neurology, Institute for Multiple Sclerosis Research and Hertie Foundation, University Medical Centre G\u00f6ttingen, G\u00f6ttingen, Germany"},{"name":"Deptartment of Neuroimmunology, Institute for Multiple Sclerosis Research and Hertie Foundation, University Medical Centre G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,2,4]]},"reference":[{"key":"2021122010011300000_cei12194-bib-0001","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/mus.23302","article-title":"Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan","volume":"45","author":"Furst","year":"2012","journal-title":"Muscle Nerve"},{"key":"2021122010011300000_cei12194-bib-0002","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/1759720X11424460","article-title":"Juvenile dermatomyositis: new insights and new treatment strategies","volume":"4","author":"Martin","year":"2012","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2021122010011300000_cei12194-bib-0003","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(99)05157-0","article-title":"Dermatomyositis","volume":"355","author":"Callen","year":"2000","journal-title":"Lancet"},{"key":"2021122010011300000_cei12194-bib-0004","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3109\/s10165-012-0663-4","article-title":"Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease","volume":"23","author":"Sato","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2021122010011300000_cei12194-bib-0005","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s11926-011-0169-7","article-title":"Malignancy in myositis","volume":"13","author":"Zahr","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"2021122010011300000_cei12194-bib-0006","first-page":"128","article-title":"The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum","volume":"31","author":"Ghazi","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2021122010011300000_cei12194-bib-0007","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00296-012-2545-7","article-title":"Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients","volume":"33","author":"Sun","year":"2013","journal-title":"Rheumatol Int"},{"key":"2021122010011300000_cei12194-bib-0008","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","article-title":"Microvascular deposition of complement membrane attack complex in dermatomyositis","volume":"314","author":"Kissel","year":"1986","journal-title":"N Engl J Med"},{"key":"2021122010011300000_cei12194-bib-0009","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"2021122010011300000_cei12194-bib-0010","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11926-010-0101-6","article-title":"Dermatomyositis and type 1 interferons","volume":"12","author":"Greenberg","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"2021122010011300000_cei12194-bib-0011","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/ar3531","article-title":"Type I interferon pathway in adult and juvenile dermatomyositis","volume":"13","author":"Baechler","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2021122010011300000_cei12194-bib-0012","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/brain\/awn053","article-title":"Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle","volume":"131","author":"Schmidt","year":"2008","journal-title":"Brain"},{"key":"2021122010011300000_cei12194-bib-0013","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1046\/j.1365-2990.2003.00471.x","article-title":"Class I MHC detection as a diagnostic tool in noninformative muscle biopsies of patients suffering from dermatomyositis (DM)","volume":"29","author":"Civatte","year":"2003","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2021122010011300000_cei12194-bib-0014","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/BOR.0b013e3283317b31","article-title":"Role of cytokines and chemokines in idiopathic inflammatory myopathies","volume":"21","author":"De Paepe","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"2021122010011300000_cei12194-bib-0015","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1517\/17530051003713499","article-title":"Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies","volume":"4","author":"Schmidt","year":"2010","journal-title":"Expert Opin Med Diagn"},{"key":"2021122010011300000_cei12194-bib-0016","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0560.2007.00770.x","article-title":"Cutaneous lesions of dermatomyositis with supervening fibrosis","volume":"35","author":"Magro","year":"2008","journal-title":"J Cutan Pathol"},{"key":"2021122010011300000_cei12194-bib-0017","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0190-9622(91)70186-6","article-title":"Immunopathologic study of skin lesions in dermatomyositis","volume":"25","author":"Hausmann","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"2021122010011300000_cei12194-bib-0018","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/archderm.1995.01690240040007","article-title":"Membrane attack complex deposits in cutaneous lesions of dermatomyositis","volume":"131","author":"Mascaro","year":"1995","journal-title":"Arch Dermatol"},{"key":"2021122010011300000_cei12194-bib-0019","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mus.10313","article-title":"Inflammatory myopathies: clinical, diagnostic and therapeutic aspects","volume":"27","author":"Mastaglia","year":"2003","journal-title":"Muscle Nerve"},{"key":"2021122010011300000_cei12194-bib-0020","doi-asserted-by":"crossref","first-page":"369432","DOI":"10.1155\/2012\/369432","article-title":"The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy","volume":"2012","author":"De Paepe","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2021122010011300000_cei12194-bib-0021","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1212\/WNL.54.1.65","article-title":"Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies","volume":"54","author":"Choi","year":"2000","journal-title":"Neurology"},{"key":"2021122010011300000_cei12194-bib-0022","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0b013e31827d7f16","article-title":"Major histocompatibility complex class I and II expression in idiopathic inflammatory myopathy","author":"Das","year":"2013","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2021122010011300000_cei12194-bib-0023","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/ana.410230111","article-title":"Expression of immunoreactive major histocompatibility complex products in human skeletal muscles","volume":"23","author":"Karpati","year":"1988","journal-title":"Ann Neurol"},{"key":"2021122010011300000_cei12194-bib-0024","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/mus.22279","article-title":"Necrotizing myopathy: clinicoserologic associations","volume":"45","author":"Ellis","year":"2012","journal-title":"Muscle Nerve"},{"key":"2021122010011300000_cei12194-bib-0025","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp.73.4.420","article-title":"Myopathy with antibodies to the signal recognition particle: clinical and pathological features","volume":"73","author":"Miller","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122010011300000_cei12194-bib-0026","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2990.2012.01302.x","article-title":"Immune-mediated necrotizing myopathies \u2013 a heterogeneous group of diseases with specific myopathological features [Review]","volume":"38","author":"Stenzel","year":"2012","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2021122010011300000_cei12194-bib-0027","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.ajpath.2012.08.033","article-title":"Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile","volume":"181","author":"Preusse","year":"2012","journal-title":"Am J Pathol"},{"key":"2021122010011300000_cei12194-bib-0028","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/ard.2006.052191","article-title":"Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2021122010011300000_cei12194-bib-0029","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2021122010011300000_cei12194-bib-0030","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/art.30344","article-title":"Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy","volume":"63","author":"Benveniste","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2021122010011300000_cei12194-bib-0031","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/BOR.0b013e32834b324b","article-title":"Necrotizing autoimmune myopathy","volume":"23","author":"Liang","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"2021122010011300000_cei12194-bib-0032","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s00415-003-1027-y","article-title":"Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy","volume":"250","author":"Bronner","year":"2003","journal-title":"J Neurol"},{"key":"2021122010011300000_cei12194-bib-0033","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11910-011-0232-9","article-title":"Update on toxic myopathies","volume":"12","author":"Mastaglia","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2021122010011300000_cei12194-bib-0034","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.jocn.2008.01.011","article-title":"Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis","volume":"15","author":"Needham","year":"2008","journal-title":"J Clin Neurosci"},{"key":"2021122010011300000_cei12194-bib-0035","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1093\/brain\/awr217","article-title":"A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities","volume":"134","author":"Cox","year":"2011","journal-title":"Brain"},{"key":"2021122010011300000_cei12194-bib-0036","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain"},{"key":"2021122010011300000_cei12194-bib-0037","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00415-009-5229-9","article-title":"Detecting dysphagia in inclusion body myositis","volume":"256","author":"Cox","year":"2009","journal-title":"J Neurol"},{"key":"2021122010011300000_cei12194-bib-0038","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"key":"2021122010011300000_cei12194-bib-0039","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1212\/WNL.55.9.1385","article-title":"Epidemiology of inclusion body myositis in the Netherlands: a nationwide study","volume":"55","author":"Badrising","year":"2000","journal-title":"Neurology"},{"key":"2021122010011300000_cei12194-bib-0040","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nmd.2009.11.003","article-title":"Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008","volume":"20","author":"Hilton-Jones","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"2021122010011300000_cei12194-bib-0041","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/NEN.0b013e31826183c8","article-title":"Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis","volume":"71","author":"Askanas","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"2021122010011300000_cei12194-bib-0042","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/jnnp.2009.174276","article-title":"Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of alphaB-crystallin is associated with amyloid precursor protein and accumulation of beta-amyloid","volume":"80","author":"Muth","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122010011300000_cei12194-bib-0043","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/brain\/aws046","article-title":"Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1beta-induced accumulation of beta-amyloid and cell death","volume":"135","author":"Schmidt","year":"2012","journal-title":"Brain"},{"key":"2021122010011300000_cei12194-bib-0044","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/ana.21115","article-title":"Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis","volume":"61","author":"Lunemann","year":"2007","journal-title":"Ann Neurol"},{"key":"2021122010011300000_cei12194-bib-0045","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1074\/jbc.M110.159392","article-title":"TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells","volume":"286","author":"Keller","year":"2011","journal-title":"J Biol Chem"},{"key":"2021122010011300000_cei12194-bib-0046","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2012.12.011","article-title":"TNF-alpha upregulates macroautophagic processing of APP\/beta-amyloid in a human rhabdomyosarcoma cell line","volume":"325","author":"Keller","year":"2013","journal-title":"J Neurol Sci"},{"key":"2021122010011300000_cei12194-bib-0047","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11882-012-0319-7","article-title":"Ocular myositis","volume":"13","author":"Fraser","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"2021122010011300000_cei12194-bib-0048","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.autrev.2012.06.004","article-title":"Overlap connective tissue disease syndromes","volume":"12","author":"Laccarino","year":"2013","journal-title":"Autoimmun Rev"},{"key":"2021122010011300000_cei12194-bib-0049","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0738-081X(88)90046-6","article-title":"A rheumatologist's view of polymyositis\/dermatomyositis: extracutaneous and extramuscular involvement and overlap syndromes","volume":"6","author":"Romans","year":"1988","journal-title":"Clin Dermatol"},{"key":"2021122010011300000_cei12194-bib-0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/rheumatology\/35.4.305","article-title":"Polymyositis-associated overlap syndromes","volume":"35","author":"Venables","year":"1996","journal-title":"Br J Rheumatol"},{"key":"2021122010011300000_cei12194-bib-0051","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11926-012-0246-6","article-title":"Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment","volume":"14","author":"Mimori","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"2021122010011300000_cei12194-bib-0052","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/rheumatology\/kep078","article-title":"Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression","volume":"48","author":"Gunawardena","year":"2009","journal-title":"Rheumatology (Oxf)"},{"key":"2021122010011300000_cei12194-bib-0053","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/art.24631","article-title":"Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease","volume":"60","author":"Richards","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021122010011300000_cei12194-bib-0054","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study","volume":"147","author":"Hamaguchi","year":"2011","journal-title":"Arch Dermatol"},{"key":"2021122010011300000_cei12194-bib-0055","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/BOR.0b013e328358bd85","article-title":"Myositis autoantibodies","volume":"24","author":"Casciola-Rosen","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"2021122010011300000_cei12194-bib-0056","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/BOR.0b013e328313bff4","article-title":"Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis","volume":"20","author":"Gunawardena","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"2021122010011300000_cei12194-bib-0057","doi-asserted-by":"crossref","first-page":"e20266","DOI":"10.1371\/journal.pone.0020266","article-title":"Autoantibodies against a 43 KDa muscle protein in inclusion body myositis","volume":"6","author":"Salajegheh","year":"2011","journal-title":"PloS One"},{"key":"2021122010011300000_cei12194-bib-0058","doi-asserted-by":"crossref","first-page":"e46709","DOI":"10.1371\/journal.pone.0046709","article-title":"Autoantibodies produced at the site of tissue damage provide evidence of humoral autoimmunity in inclusion body myositis","volume":"7","author":"Ray","year":"2012","journal-title":"PLOS One"},{"key":"2021122010011300000_cei12194-bib-0059","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5\u2032-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Larman","year":"2013","journal-title":"Ann Neurol"},{"key":"2021122010011300000_cei12194-bib-0060","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5\u2032-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann Neurol"},{"key":"2021122010011300000_cei12194-bib-0061","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/BOR.0b013e3283317fa5","article-title":"Paraneoplastic myopathy","volume":"21","author":"Danko","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"2021122010011300000_cei12194-bib-0062","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000308714","article-title":"Paraneoplastic necrotizing myopathy with a mild inflammatory component: a case report and review of the literature","volume":"3","author":"Wegener","year":"2010","journal-title":"Case Rep Oncol"},{"key":"2021122010011300000_cei12194-bib-0063","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2459\/JCM.0b013e32833cdca8","article-title":"Cardiological features in idiopathic inflammatory myopathies","volume":"11","author":"Bazzani","year":"2010","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2021122010011300000_cei12194-bib-0064","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000093866","article-title":"Needle electromyographic findings in 98 patients with myositis","volume":"55","author":"Blijham","year":"2006","journal-title":"Eur Neurol"},{"key":"2021122010011300000_cei12194-bib-0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1749-6632.2009.04386.x","article-title":"Magnetic resonance imaging of the idiopathic inflammatory myopathies: structural and clinical aspects","volume":"1154","author":"Curiel","year":"2009","journal-title":"Ann NY Acad Sci"},{"key":"2021122010011300000_cei12194-bib-0066","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/annrheumdis-2011-200564","article-title":"Screening for interstitial lung disease in systemic sclerosis: the diagnostic accuracy of HRCT image series with high increment and reduced number of slices","volume":"71","author":"Winklehner","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2021122010011300000_cei12194-bib-0067","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1590\/S0482-50042012000400009","article-title":"Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"52","author":"Pereira","year":"2012","journal-title":"Rev Bras Reumatol"},{"key":"2021122010011300000_cei12194-bib-0068","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.clineuro.2004.02.024","article-title":"Oropharyngeal dysphagia in polymyositis\/dermatomyositis","volume":"107","author":"Ertekin","year":"2004","journal-title":"Clin Neurol Neurosurg"},{"key":"2021122010011300000_cei12194-bib-0069","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00455-011-9338-0","article-title":"Dysphagia in inflammatory myopathy: self-report, incidence, and prevalence","volume":"27","author":"Mulcahy","year":"2012","journal-title":"Dysphagia"},{"key":"2021122010011300000_cei12194-bib-0070","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00020840-200312000-00014","article-title":"Evaluation of oropharyngeal dysphagia: which diagnostic tool is superior?","volume":"11","author":"Langmore","year":"2003","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"2021122010011300000_cei12194-bib-0071","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF02950398","article-title":"Dermatomyositis successfully treated by prednisone","volume":"33","author":"Micks","year":"1958","journal-title":"Ir J Med Sci"},{"key":"2021122010011300000_cei12194-bib-0072","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.nmd.2010.03.011","article-title":"Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial","volume":"20","author":"van de Vlekkert","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"2021122010011300000_cei12194-bib-0073","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1212\/WNL.48.5.1234","article-title":"Steroid myopathy in cancer patients","volume":"48","author":"Batchelor","year":"1997","journal-title":"Neurology"},{"issue":"8","key":"2021122010011300000_cei12194-bib-0074","first-page":"CD003643","article-title":"Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis","author":"Gordon","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122010011300000_cei12194-bib-0075","first-page":"1729","article-title":"Improved therapeutic index of methotrexate with \u2018leucovorin rescue\u2019","volume":"33","author":"Levitt","year":"1973","journal-title":"Cancer Res"},{"issue":"Suppl. 15","key":"2021122010011300000_cei12194-bib-0076","first-page":"S53","article-title":"Safety and side effects of i.v. immunoglobulin therapy","volume":"14","author":"Nydegger","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"2021122010011300000_cei12194-bib-0077","doi-asserted-by":"crossref","first-page":"A515","DOI":"10.1016\/j.autrev.2011.11.021","article-title":"Pregnancy issues in scleroderma","volume":"11","author":"Lidar","year":"2012","journal-title":"Autoimmun Rev"},{"key":"2021122010011300000_cei12194-bib-0078","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2165\/11596240-000000000-00000","article-title":"Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management","volume":"71","author":"Makol","year":"2011","journal-title":"Drugs"},{"key":"2021122010011300000_cei12194-bib-0079","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nrrheum.2009.103","article-title":"Management of RA medications in pregnant patients","volume":"5","author":"Ostensen","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"2021122010011300000_cei12194-bib-0080","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2021122010011300000_cei12194-bib-0081","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2021122010011300000_cei12194-bib-0082","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/rheumatology\/ker088","article-title":"Rituximab treatment in patients with refractory inflammatory myopathies","volume":"50","author":"Mahler","year":"2011","journal-title":"Rheumatology (Oxf)"},{"key":"2021122010011300000_cei12194-bib-0083","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A randomized, pilot trial of etanercept in dermatomyositis","volume":"70","author":"Muscle Study Group","year":"2011","journal-title":"Ann Neurol"},{"key":"2021122010011300000_cei12194-bib-0084","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/BOR.0b013e32834f19f5","article-title":"Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies","volume":"24","author":"Alexanderson","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"2021122010011300000_cei12194-bib-0085","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/brain\/112.3.727","article-title":"Inclusion body myositis. Observations in 40 patients","volume":"112","author":"Lotz","year":"1989","journal-title":"Brain"},{"key":"2021122010011300000_cei12194-bib-0086","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1212\/01.WNL.0000071852.27182.C7","article-title":"Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study","volume":"61","author":"Lindberg","year":"2003","journal-title":"Neurology"},{"key":"2021122010011300000_cei12194-bib-0087","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1212\/01.wnl.0000192258.32408.54","article-title":"Pilot trial of etanercept in the treatment of inclusion-body myositis","volume":"66","author":"Barohn","year":"2006","journal-title":"Neurology"},{"key":"2021122010011300000_cei12194-bib-0088","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/WNL.58.7.1081","article-title":"A pilot randomized trial of oxandrolone in inclusion body myositis","volume":"58","author":"Rutkove","year":"2002","journal-title":"Neurology"},{"key":"2021122010011300000_cei12194-bib-0089","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1212\/WNL.57.9.1566","article-title":"Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis","volume":"57","author":"Muscle Study Group","year":"2001","journal-title":"Neurology"},{"key":"2021122010011300000_cei12194-bib-0090","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/01.WNL.0000134675.98525.79","article-title":"Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis","volume":"63","author":"Muscle Study Group","year":"2004","journal-title":"Neurology"},{"key":"2021122010011300000_cei12194-bib-0091","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ana.10121","article-title":"Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo","volume":"51","author":"Badrising","year":"2002","journal-title":"Ann Neurol"},{"key":"2021122010011300000_cei12194-bib-0092","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"key":"2021122010011300000_cei12194-bib-0093","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1212\/WNL.44.8.1516","article-title":"Inclusion body myositis: treatment with intravenous immunoglobulin","volume":"44","author":"Amato","year":"1994","journal-title":"Neurology"},{"key":"2021122010011300000_cei12194-bib-0094","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"2021122010011300000_cei12194-bib-0095","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","article-title":"A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM","volume":"56","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"key":"2021122010011300000_cei12194-bib-0096","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","article-title":"High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study","volume":"247","author":"Walter","year":"2000","journal-title":"J Neurol"},{"key":"2021122010011300000_cei12194-bib-0097","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/WNL.58.2.326","article-title":"Intravenous immunoglobulin for dysphagia of inclusion body myositis","volume":"58","author":"Cherin","year":"2002","journal-title":"Neurology"},{"key":"2021122010011300000_cei12194-bib-0098","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/CCRep.S10200","article-title":"Balloon dilation in sporadic inclusion body myositis patients with dysphagia","volume":"6","author":"Murata","year":"2013","journal-title":"Clin Med Insights Case Rep"},{"key":"2021122010011300000_cei12194-bib-0099","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10072-011-0657-6","article-title":"Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis","volume":"32","author":"Sancricca","year":"2011","journal-title":"Neurol Sci"},{"key":"2021122010011300000_cei12194-bib-0100","first-page":"482","article-title":"Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis","volume":"13","author":"Phukan","year":"2010","journal-title":"IDrugs"},{"key":"2021122010011300000_cei12194-bib-0101","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/0884533609332005","article-title":"Senescent swallowing: impact, strategies, and interventions","volume":"24","author":"Ney","year":"2009","journal-title":"Nutr Clin Pract"},{"key":"2021122010011300000_cei12194-bib-0102","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/acr.20325","article-title":"Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients","volume":"62","author":"Marie","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021122010011300000_cei12194-bib-0103","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4065\/82.4.441","article-title":"Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients","volume":"82","author":"Oh","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"2021122010011300000_cei12194-bib-0104","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/PHM.0b013e31818a50e2","article-title":"Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome","volume":"87","author":"Oh","year":"2008","journal-title":"Am J Phys Med Rehabil"},{"key":"2021122010011300000_cei12194-bib-0105","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1155\/2004\/360537","article-title":"Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis","volume":"18","author":"Liu","year":"2004","journal-title":"Can J Gastroenterol"},{"key":"2021122010011300000_cei12194-bib-0106","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000100898","article-title":"Risk factors for aspiration pneumonia after percutaneous endoscopic gastrostomy","volume":"53","author":"Kitamura","year":"2007","journal-title":"Gerontology"},{"key":"2021122010011300000_cei12194-bib-0107","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.anl.2009.04.007","article-title":"Polymyositis with dysphagia treated with endoscopic balloon dilatation","volume":"36","author":"Nagano","year":"2009","journal-title":"Auris Nasus Larynx"},{"key":"2021122010011300000_cei12194-bib-0108","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00455-011-9384-7","article-title":"Pharyngeal dysphagia in inflammatory muscle diseases resulting from impaired suprahyoid musculature","volume":"27","author":"Langdon","year":"2012","journal-title":"Dysphagia"},{"key":"2021122010011300000_cei12194-bib-0109","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00115-010-2970-3","article-title":"Standard treatment for myositis and muscular dystrophies","volume":"82","author":"Schmidt","year":"2011","journal-title":"Nervenarzt"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12194","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/175\/3\/349\/41789141\/cei12194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/175\/3\/349\/41789141\/cei12194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T04:47:51Z","timestamp":1715921271000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/175\/3\/349\/6421195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,4]]},"references-count":109,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,2,4]]},"published-print":{"date-parts":[[2014,2,4]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.12194","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2014,3]]},"published":{"date-parts":[[2014,2,4]]}}}